What Are the Long-Term Effects of TRT?
- Cheryl Felt
- November 22, 2026
- 10 min read
TRT
Table of Contents
Long-term effects of TRT is one of the most important questions anyone considering testosterone replacement therapy should be able to answer clearly before beginning treatment. Not because the long-term picture is alarming, but because making an informed decision requires understanding what sustained testosterone therapy actually does over years of use, both the well-documented benefits and the risks that require ongoing management.
The honest answer is that the evidence on long-term TRT has improved substantially over the past decade. Several concerns that were previously theoretical or based on older data have been clarified by large-scale clinical trials. Other concerns remain real and require consistent clinical monitoring to manage responsibly. This article covers both sides of that picture.
1. Why Long-Term TRT Requires Its Own Conversation
Many patients who begin TRT are appropriately focused on the near-term question: will this help with my symptoms? The answer, for patients with confirmed low testosterone, is consistently yes in the short to medium term.
But TRT is often a long-term or indefinite commitment. The hormonal deficiency it addresses does not resolve on its own in most cases, and stopping treatment typically means returning to the symptomatic state that prompted starting it. This means the more clinically relevant question for most patients is not just whether TRT works, but what happens over years and decades of sustained use.
The long-term picture is genuinely more reassuring than it appeared a decade ago, when concerns about cardiovascular risk in particular created significant uncertainty. Large, well-designed trials have clarified the cardiovascular picture substantially. At the same time, certain effects, primarily on red blood cell count, fertility, and natural testosterone production, require ongoing attention from both patients and providers.
For patients who are just beginning to evaluate whether TRT is appropriate, our overview of male testosterone replacement therapy provides a foundation for that initial assessment.
2. Long-Term Benefits Supported by Evidence
The long-term benefit profile of TRT extends across several domains that develop and compound over years of treatment.
Bone mineral density improves significantly with sustained TRT. As covered in detail in our article on TRT and bone health, the Testosterone Trials demonstrated meaningful increases in spine and hip bone density within one year of treatment, with continued improvement in longer follow-up.
Body composition improvement is one of the more consistently reported long-term effects. Lean mass increases and fat mass decreases over sustained TRT, with visceral fat responding particularly well. These changes are most meaningful when TRT is combined with resistance training and adequate dietary protein.
Sexual function and desire typically improve early in treatment and are maintained over the long term in patients who remain on appropriately dosed therapy. Long-term data consistently shows sustained improvements in libido and sexual function in men with hypogonadism who continue treatment.
Mood, energy, and cognitive function show long-term maintenance effects. Depression symptoms in men with low testosterone improve with TRT, and the energy and motivation improvements that most patients notice early in treatment are generally sustained.
Metabolic markers including insulin sensitivity, lipid profiles, and blood pressure often show sustained improvements over long-term TRT in patients with obesity-related metabolic dysfunction, particularly when combined with weight management.
3. Cardiovascular Effects of Long-Term TRT
The cardiovascular safety of TRT has been the most contentious area in the long-term evidence picture. An older FDA advisory and a now-retracted study from 2010 created concern about increased cardiovascular risk, and a 2010 trial that was stopped early due to adverse cardiovascular events added to that concern in the clinical community.
The picture changed substantially with the TRAVERSE trial, a large randomized controlled trial published in the New England Journal of Medicine in 2023. The trial enrolled over 5,200 men aged forty-five to eighty with hypogonadism and either established cardiovascular disease or high cardiovascular risk, and followed them for a median of approximately 3.4 years.
The primary finding was that testosterone therapy was noninferior to placebo for the composite cardiovascular endpoint of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. In other words, testosterone therapy in this high-risk population did not increase the risk of major adverse cardiovascular events compared to placebo.
The TRAVERSE trial also found a higher incidence of atrial fibrillation and pulmonary embolism in the testosterone group, effects that require clinical attention and may be relevant for individual patient risk assessment. These findings do not negate the overall noninferior cardiovascular profile, but they represent specific signals that warrant discussion with providers in patients with relevant risk factors.
4. Hematological Effects: Managing Erythrocytosis
Erythrocytosis, an increase in red blood cell count and hematocrit, is the most commonly encountered hematological effect of TRT and one of the most important to monitor over the long term.
Testosterone stimulates erythropoiesis, the production of red blood cells. This is a physiological effect, not a pathological one at moderate levels. However, when hematocrit rises above approximately 54 percent, the increased blood viscosity raises the risk of thromboembolic events including deep vein thrombosis and pulmonary embolism.
Regular complete blood count monitoring is essential for all men on long-term TRT. When hematocrit rises above acceptable thresholds, options include dose reduction, switching to a different delivery method (injectable forms carry higher erythrocytosis risk than topical forms in most patients), or therapeutic phlebotomy.
Erythrocytosis is a manageable side effect in the vast majority of patients when monitoring is consistent. It becomes a risk primarily when it goes undetected, which is a consequence of inadequate follow-up rather than an inherent problem with TRT itself.
5. Effects on Fertility and Testicular Function
Long-term exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, reducing the hormonal signals that stimulate natural testosterone production and sperm production in the testes. This effect is predictable and occurs to some degree in essentially all men on TRT.
The practical consequence for fertility is that long-term TRT significantly reduces sperm count and can produce azoospermia (zero sperm count) in a substantial proportion of men. For men who have completed their families or do not plan to have children, this is primarily a consideration for testicle size and function rather than a clinical problem requiring intervention.
For men who may want to father children in the future, fertility preservation planning before starting TRT is important. Options include sperm banking before beginning treatment and the use of fertility-preserving protocols, which typically include human chorionic gonadotropin (hCG) alongside TRT to maintain testicular function and sperm production.
Recovery of fertility after stopping long-term TRT is possible in most men, but the timeline is variable and not guaranteed to be complete, particularly after many years of treatment. Earlier consultation with a fertility specialist for men with future fertility intentions is recommended before beginning TRT.
6. Prostate Health and Long-Term TRT
Prostate health monitoring is a standard and important component of long-term TRT management, though the relationship between testosterone and prostate cancer has been substantially reframed over the past two decades.
The older saturation model proposed that testosterone fuels prostate cancer growth in a linear fashion. Current evidence supports the saturation model, which holds that prostate tissue becomes saturated with androgen at relatively low testosterone levels, and that increasing testosterone from deficient to physiological does not meaningfully increase prostate cancer risk in men without pre-existing disease.
This has been supported by the TRAVERSE trial, which showed no significant increase in prostate cancer incidence in the testosterone group compared to placebo over 3.4 years of follow-up.
However, testosterone therapy is still contraindicated in men with known or suspected prostate cancer, and regular prostate-specific antigen (PSA) monitoring remains standard practice. Any significant rise in PSA during TRT warrants urological evaluation. Screening for pre-existing prostate disease before starting TRT is part of responsible clinical management.
For patients whose long-term TRT program includes prostate monitoring and comprehensive follow-up, understanding what those check-ins involve is covered in our overview of the TRT monitoring process.
7. Frequently Asked Questions
Is it safe to stay on TRT indefinitely?
For most appropriately selected men who receive consistent clinical monitoring, long-term TRT is considered safe and clinically appropriate. The TRAVERSE trial provides the most robust evidence to date that TRT does not increase major cardiovascular risk in high-risk populations over approximately three years. Managing hematocrit, PSA, and other relevant markers through regular labs is the primary requirement for sustained safe use. The decision to continue TRT long term is made in partnership with a provider based on ongoing clinical assessment.
Does TRT cause testosterone levels to stay suppressed after stopping?
The hypothalamic-pituitary-gonadal axis suppression caused by TRT is largely reversible in most men after stopping treatment, but recovery time varies. Younger men with shorter treatment duration typically recover natural testosterone production more quickly. Men who have been on TRT for many years may take six to eighteen months or more for natural production to recover fully, and some men do not return to pre-treatment levels. This is a factor to discuss with a provider before stopping TRT, particularly if the original reason for treatment was a reversible cause.
Does long-term TRT cause liver damage?
Oral methylated testosterone formulations carry liver toxicity risk and are rarely used in modern clinical practice for that reason. Injectable, topical, and subcutaneous pellet formulations do not carry meaningful hepatotoxic risk. Liver function monitoring is not typically required for non-oral TRT. Patients who encounter claims about TRT and liver damage should clarify whether the concern applies to oral formulations or to the delivery methods actually in current clinical use.
Can long-term TRT cause heart problems?
The cardiovascular picture for TRT has been significantly clarified by the TRAVERSE trial, which found no increased risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) over approximately 3.4 years compared to placebo in high-risk men. The trial did find a higher incidence of atrial fibrillation and pulmonary embolism in the testosterone group, effects that are relevant for patient-specific risk assessment. Men with established atrial fibrillation or significant clotting risk should discuss these findings specifically with their provider.
Does TRT affect mental health over the long term?
Long-term TRT has consistent evidence for sustained improvements in mood, depressive symptoms, and quality of life in men with hypogonadism. Some men report mood fluctuations related to dosing schedule and hormone level peaks and troughs, particularly on injectable protocols. These fluctuations can be addressed through dosing adjustments. The long-term mental health trajectory for men on appropriately managed TRT is generally positive.
What monitoring is required for long-term TRT?
Standard long-term monitoring includes complete blood count (particularly hematocrit), PSA, comprehensive metabolic panel, and testosterone levels. Frequency varies by clinical status and stability, but annual comprehensive labs are typical for patients who have reached a stable dose. Men with elevated hematocrit may require more frequent blood count monitoring. The specific monitoring schedule is determined by the treating provider based on individual clinical factors.
Key Takeaways
- Long-term TRT produces documented benefits including improvements in bone mineral density, body composition, sexual function, and mood stability that develop and sustain over years of treatment
- The TRAVERSE trial, published in 2023, found no increased risk of major adverse cardiovascular events in men with hypogonadism and cardiovascular disease or high cardiovascular risk treated with testosterone for approximately three years
- Erythrocytosis (elevated red blood cell count) is the most commonly managed hematological effect of TRT and requires regular monitoring; it is manageable but not ignorable
- Long-term TRT suppresses the body’s natural testosterone production and often leads to reduced sperm production; this effect is largely reversible after stopping treatment but requires planning for men considering fertility
- Prostate health monitoring is a standard component of long-term TRT management; current evidence does not support a causal relationship between TRT and prostate cancer in men without pre-existing prostate disease
- The quality of long-term TRT outcomes is substantially determined by the quality of ongoing clinical management, including regular labs and provider oversight
Schedule a TRT Consultation.
If you want to understand whether TRT is appropriate for your situation and what responsible long-term management involves, a consultation through our testosterone replacement therapy program is the right starting point.
Disclaimer:
This content is for informational purposes only and does not constitute medical advice. Testosterone replacement therapy involves prescription treatment requiring individualized assessment, monitoring, and ongoing provider supervision. Results vary. Consult a qualified healthcare provider before starting, adjusting, or stopping any hormone therapy.
References
- New England Journal of Medicine. TRAVERSE Trial: Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy. https://www.nejm.org/doi/full/10.1056/NEJMoa2215025
- Journal of Clinical Endocrinology and Metabolism. Long-term effects of testosterone therapy on bone, body composition, and sexual function. https://academic.oup.com/jcem